Targets › SRC
9 programs from 9 companies in 13 trials: 7 Phase 1, 4 Phase 2, 2 Phase 4; Oncology, Other, Infectious disease; next expected readout Nov 2026.
Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription,…. (UniProt, P12931)
Open in Phaseline: the race on SRC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The Skin Center Dermatology Group | Tirbanibulin Tyrosine-protein kinase SRC inhibitor | SRC | Phase 4 | Warts Hand; Cell Carcinoma; Keratinocyte Carcinoma | Dec 2026 |
| Almirall | Tirbanibulin Tyrosine-protein kinase SRC inhibitor | SRC | Phase 4 | Keratosis, Actinic | Jul 2027 |
| Amsterdam UMC, location VUmc | Saracatinib (AZD0530) Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor | ABL1, SRC | Phase 2 | Fibrodysplasia Ossificans Progressiva | Nov 2026 |
| Baylor College of Medicine | Bosutinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor | ABL1, SRC, HCK, LYN, BCR | Phase 2 | Chronic Myeloid Leukemia | Nov 2028 |
| Ruijin Hospital | Avastinib BCR-ABL and SRC family kinase inhibitor | ABL1, SRC | Phase 2 | AML | Mar 2030 |
| Nuvectis Pharma | NXP900 SRC family kinase inhibitor | SRC | Phase 1 | EGFR Mutation Positive Non-small Cell Lung Cancer; Advanced Solid Tumor; ALK Positive | Dec 2026 |
| Turning Point Therapeutics | elzovantinib (TPX-0022) MET/CSF1R/SRC inhibitor | MET, CSF1R, SRC | Phase 1 | Advanced Solid Tumor | Mar 2027 |
| Children's Oncology Group | Bosutinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor | ABL1, SRC, HCK, LYN, BCR | Phase 1 | Philadelphia Chromosome Positive CML | Jul 2028 |
| National Jewish Health | Saracatinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor | ABL1, SRC | Phase 1 | Idiopathic Pulmonary Fibrosis (IPF) | – |
Advanced Solid Tumor (2) EGFR Mutation Positive Non-small Cell Lung Cancer (1) ALK Positive (1) Chronic Myeloid Leukemia (1) AML (1) Fibrodysplasia Ossificans Progressiva (1) Warts Hand (1) Cell Carcinoma (1) Keratinocyte Carcinoma (1) Keratosis, Actinic (1) Philadelphia Chromosome Positive CML (1) Idiopathic Pulmonary Fibrosis (IPF) (1)
small molecule (8), other (1)
Nuvectis Pharma (1) Baylor College of Medicine (1) Turning Point Therapeutics (1) Ruijin Hospital (1) Amsterdam UMC, location VUmc (1) The Skin Center Dermatology Group (1) Almirall (1) Children's Oncology Group (1) National Jewish Health (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.